Peregrine Pharmaceuticals (PPHM) Tops Q4 EPS by 1c
Get Alerts PPHM Hot Sheet
Join SI Premium – FREE
Peregrine Pharmaceuticals (NASDAQ: PPHM) reported Q4 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $6.47 million versus the consensus estimate of $4.75 million.
Contract manufacturing revenues from Avid's clinical and commercial biomanufacturing services provided to its third-party clients were $22,294,000 for FY 2014 compared to $21,333,000 for FY 2013. Current contract manufacturing commitments from Avid's third-party customers are in excess of $26 million, covering services to be provided during FY 2015 and into FY 2016. Based on these current commitments, Peregrine expects contract manufacturing revenues for FY 2015 to be between $19 and $23 million. In addition to providing biomanufacturing services to its third-party clients, Avid will continue to support the potential commercialization of bavituximab.
For earnings history and earnings-related data on Peregrine Pharmaceuticals (PPHM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbus revenue rises, delivers 142 commercial aircraft in Q1
- Esquire Financial Holdings, Inc. (ESQ) Tops Q1 EPS by 3c
- EMCOR Group (EME) Tops Q1 EPS by 133c, raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!